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Background. Hemophagocytic syndrome (HPS) is characterized by a hyperinﬂammatory reaction followed by alteration in
cytotoxic function of Th1 lymphocytes and natural killer cells. We report a rare case of a patient that presented with fever
and pancytopenia due to HPS associated with Hodgkin’s lymphoma (HL). Case Report. A 69-year-old Caucasian woman was
admitted presenting with complaints of fever, seizures, and low back pain that had lasted for two weeks. Laboratorial data showed
pancytopenia. Bone marrow biopsy revealed inﬁltration by Reed-Sternberg cells and hemophagocytosis signs. Imaging studies
showed mediastinal lymph nodes (stage IV B). She had been treated with ABVD (doxorubicin, bleomycin, vinblastine, and
dacarbazine) followed by a good response. Conclusion. HPS associated with HL is a very rare and lethal disease, with mortality
rates of about 15% to 60%. The prompt diagnosis of the underlying lymphoma may be an important strategy for optimizing the
clinical approach and outcome.
1.Introduction
Hemophagocytic syndrome (HPS) is characterized by the
proliferation of benign macrophages responsible for exten-
sive phagocytosis of hematopoietic cells due to a hyperin-
ﬂammatory reaction that may cause alteration in cytotoxic
function of T lymphocytes and natural killer cells [1, 2].
One of the most consistent ﬁndings is low or absent cyto-
toxicity activity of natural killer (NK) cells. This biological
event is related to a defective production of cytokines and
anomalous inﬂammatory reaction that change the normal
behavior of the immune system leading to deregulated cell
signaling. Some studies suggest that the lack of perforins,
a hydrophobic protein that is packaged into specialized
cytotoxicity granules of human natural killer cells (CD56low,
CD8−), natural killer T cells (CD56low,C D 8 +low), and
activated CD8+ T helper 1 lymphocytes (Th1), results in
insuﬃciency to regulate or terminate a immune response
[1, 3–5]. These perforins seem to act with granzymes, a
serine protease, leading to induced apoptosis in the target
cells. Mutation in the perforin gene accounts for about 20%–
40% of hemophagocytic lymphohistiocytosis subjects [3, 6].
HPS is a clinical pathological disease described by histiocytic
proliferation, fever, hepatosplenomegaly, cytopenia, altered
liver function, hyperferritinemia, hypertriglyceridemia, low
plasma ﬁbrinogen levels, and/or frequently coagulopathy
disorders [1, 3, 4, 7]. It can be genetic, when associated with
inherited alteration of T lymphocytes and NK cells behavior,
or acquired, associated with infection, mainly Epstein-Barr
virus (EBV), autoimmune, or immunodeﬁciency status. It is
rarely associated with B cell lymphoma [1, 4]. The treatment
is very diﬃcult, and some studies [3, 4, 8]r e p o r tab a d
therapeutic prognosis sometimes, with a clinical response
to chemotherapy rate of about 65% [4]. In this paper, we2 Case Reports in Medicine
report a rare case of a patient that ﬁrst presented with
fever and pancytopenia due to hemophagocytosis associated
withHodgkin’slymphoma(HL)andhighlightthediﬃculties
regarding diagnosis and clinical approach.
2.CaseReport
A69-year-oldCaucasianwomanwasadmittedtotheinternal
medicine ward presenting with symptoms of fever, seizures,
and low back pain that had lasted for two weeks, followed
by asthenia and dyspnea on moderate exertion. She had a
medical history of probable inﬂammatory oculomotor palsy
(under chronic corticotherapy), systemic arterial hyperten-
sion, dyslipidemia, obesity, and hyperhomocysteinemia. She
had irrelevant familial history, without consanguineous par-
ents. On physical examination, she had good performance
status, left ptosis, left oculomotor palsy, no palpable lymph
node, normal cardiopulmonary and abdominal examina-
tions, and no peripheral edemas. The subsequent labora-
torial study revealed pancytopenia, hyperglycemia, hyper-
triglyceridemia, hyperferritinemia, low ﬁbrinogen levels,
and high β-2 microglobulin levels (Table 1). The thoracic-
abdominal computed tomography (CT) showed mediastinal
lymph nodes swelling between 12 and 15.5mm and mild
hepatosplenomegaly. The bone marrow biopsies revealed
marrow inﬁltration by Hodgkin’s lymphoma with Reed-
Sternberg cells and hemophagocytosis signs (Figure 1) (stage
IV B by Ann Arbor). The patient was submitted to high-
dose corticotherapy followed by chemotherapy (ABVD—
doxorubicin, bleomycin, vinblastine, and dacarbazine). She
had an allergic reaction to bleomycin, which was changed to
cyclophosphamide. On discharge the patient retained good
clinical status, without fever and other complains.
3. Discussion
Hodgkin’s disease was ﬁrst macroscopically described by
Thomas Hodgkin in 1832 as a primary nodal lympho-
proliferative disorder. In 1898 and 1902, Carl Sternberg
and Dorothea Reed, respectively, reported the characteristic
binucleated and multinucleated dysplastic giant cells located
in an abundant cellular background that came to be
called Reed-Sternberg cells. After 1990s, immunophenotyp-
ing and clinical data showed that this pathology basically
had two distinct entities: nodular lymphocyte-predominant
Hodgkin’s lymphoma and classic Hodgkin’s lymphoma [9].
The hemophagocytic syndrome is a very rare and lethal dis-
ease. It was ﬁrst described by Scott and Robb-Smith in 1932
who named it “histiocytic medullary reticulosis”. In 1979,
Riscall et al. ﬁrst characterized virus-associated HPS in a case
series of 19 patients. Due to the diﬃculty to express a correct
diagnosis, the incidence of HPS is diﬃcult to estimate; a
Japanese study group has reported an annual incidence of
about 1 in 800.000 [1, 10]. The mortality rate is about 15%
to 60%. HPS may be associated with EBV virus in 20%–80%
of cases, and it is predominant in males. The EBV infection
is consistently associated with HL, and older patients with
this situation have a poor prognosis and, in general, tolerate
Table 1: Laboratorial data on admission to internal medicine ward:
blood analysis.
Laboratorial data Values Reference
values
Hemoglobin 7.6g/dL 12–16
Hematocrit 23.8% 37–49
Leucocyte count 1.17 × 109/L 4.0–11.0
Neutrophils 65% 53.8–69.8
Lymphocyte 16.2% 25.3–47.3
Platelets 49 × 109/L 180–500
Albumin 33.5g/L 38–51
Total protein 53.8g/L 64–83
AST (aspartate
aminotransferase) 45U/L 10–31
ALT (alanine aminotransferase) 105U/L 10–31
Gama glutamyltransferase 719U/L 7–32
Alkaline phosphatase 274U/L 38–145
Total Bilirrubin 24.6mg/L <12
LDH (lactate dehydrogenase)
seric 417U/L 135–225
Prothrombin time 12.8 Seconds 10.5–13.5
Activated partial thromboplastin
time 28.3 Seconds 24.5–36.5
Fibrinogen level 178mg/dL 190–400
Glucose 250mg/dL 75–115
Urea 59mg/dL 10–50
Creatinine 0.91mg/dL 0.6–1.0
Ferritin 9606.00ng/mL 14.0–233
Triglycerides 6.36 g/L <1.50
C-reactive protein 5.5mg/L <3.0
β-2 microglobulin 6620g/L 700–3400
current treatments less well than young patients [11]. Some
papers hypothesize that the latent membrane protein (LPM-
1) released by tumor cells infected by EBV may induce the
production of large amounts of Th1 cytokines by Reed-
Sternberg cells, leading to hemophagocytosis [1, 6]. These
mechanisms could be responsible for intracellular signaling
that regulates the apoptosis and macrophage recruitment
resulting in cell destruction, but it is still not clear [6].
Bhagwati et al. reported that the clinical manifestation of
HPS is a result of a variable elevation of various inﬂam-
matory cytokines including interferon-γ (IFN-γ), tumor
necrosis factor-α (TNF-α), interleukin-1β (IL-1β), soluble
interleukine 2 receptor, and linterleukin-6 (IL-6) leading to
a systemic inﬂammatory response syndrome [12]. In 2005
Mazodier et al. reported that low levels of interleukin 18 may
be associated with secondary HPS in patients with underly-
ing disease, because it is a strong inducer of Th-1 response,
IFN-γ production, and stimulation of macrophages and NK
cells [13]. In 2010, Aldinucci et al. reported that the nuclear
factor-κβ (NF-κβ) and an altered JAK-STAT signaling path-
way are part of the biological mechanisms associated with
the inﬂammatory response of Hodgkin’s disease, indirectlyCase Reports in Medicine 3
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Figure 1: Bone marrow biopsies revealing Hodgkin’s disease and hemophagocytosis. (a) Hematoxylin and eosin (HE ×100), showing the
general aspect of bone marrow. (b) HE ×600, showing the Reed-Sternberg cells. (c) Blade positive to CD30. (d) HE ×600, showing in the
center of ﬁgure the hemophagocytosis signs: the macrophage with erythrocytes inside.
helping to regulate the cell death. The overexpression of the
members of the TNF receptor family, like CD30 and CD40,
is a hallmark of Hodgkin and Reed-Sternberg cells [14]. To
conﬁrm diagnosis of acquired HPS, ﬁve out of eight criteria
shouldexist:fever,splenomegaly,cytopeniainmorethantwo
cell lines (hemoglobin <90g/L or neutrophils <1 × 109/L,
e.g.), hypertriglyceridemia (fasting triglycerides more than
3mmol/L) and/or hypoﬁbrinogenemia (<1.5g/L), ferritin
more than 500ug/L, soluble CD25 ≥ 2400U/mL, decreased
or absent NK cell activity, and hemophagocytosis in bone
marrow or lymph nodes. In this case the patient had almost
all of these criteria including the bone marrow alteration
[15]. The main point of HPS treatment is to suppress
the hyperinﬂammation that is responsible for threatening
the patient’s life and treat the principal cause of this
stimulus. The corticosteroids are of fundamental importance
in reducing cytokine release and inhibiting the inﬂammatory
reaction.In2010,Herbstetal.reportedthatthecombination
of radiotherapy and chemotherapy with ABVD may improve
the tumor control and 5-year overall survival in patients
with early stage Hodgkin’s lymphoma, which was not the
case with our patient. However, it is important to note
that cardiac toxicity is associated with mediastinal radiation
and with cumulative dose of chemotherapy, in particular
doxorubicin [8]. The optimal treatment for patients with
Hodgkin’s disease and HPS has not yet been established.
ABVD chemotherapy seems a reasonable choice. Patients
with poorly responsive disease may be suitable for allo-
geneic hematopoietic stem cell transplantation with reduced
intensity conditioning in order to avoid transplant-related
complications and prevent sequential relapse [16].
4. Conclusion
Acquired hemophagocytic syndrome associated with
Hodgkin’s lymphoma is a rare, fatal, and sometimes under-
diagnosed disease, frequently triggered by viral infections
or in association with inﬂammatory disease [10, 17]. Thus,
the prompt diagnosis of the underlying lymphoma is the
most important strategy for optimizing the clinical approach
and improving the outcome. Therefore, it is important that
physician should be alert to and suspect this pathology in
cases of patients with unexplained fever, organomegaly, and
blood count alteration, such as cytopenia with more than
two lines, even if there are no palpable lymph nodes.
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